The relative expression ofB7-H3was higher and less variable among molecular subtypes than for other key molecular targets in this tumor type, includingDLL3.B7-H3expression had limited association withPD-L1expression, supporting a role as a distinct therapeutic target.B7-H3andDLL3expression by SCLC...
worked on SCLC-J1, a novel cell line obtained from a malignant pleural effusion in an advanced SCLC patient to characterize cytogenetic, genetic and cytologic aspects with immunocytochemical expression of selected antigens as well as ganglioside GD2, B7-H3, and delta-like protein 3 (DLL-3). The...
Expression Medium稀释细胞浓度至3×10viable cells/ml; [0064]3)将质粒DNA加入Opti‑MENTM I Ruduced Serum Medium中,轻轻吹打,颠倒混匀; [0065]4)轻轻颠倒ExpiFectamineTM 293Reagent 4‑5次,将ExpiFectamineTM 293Reagent和 Opti‑MENTM
CAR-NK therapy is becoming a promising approach to treat solid tumors. However, the random insertion of the CAR gene and inflexible CAR expression caused by common preparation methods significantly impact its efficacy and safety. Here we successfully est
3. Results 3.1. High Expression of B7-H3 Is Associated with Poor Survival in MB Patients B7-H3 is a known suppressive immune checkpoint that has increasingly been implicated in cancer progression [17,25]. To verify if B7-H3 could be considered a therapeutic target in MB, biopsy specimens ...